Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference23 articles.
1. Chiu MN, Bhardwaj M, Sah SP (2022) Safety profile of COVID-19 drugs in a real clinical setting. Eur J Clin Pharmacol 78(5):733–753. https://doi.org/10.1007/s00228-021-03270-2
2. Noyman I, Ekstein D, Fahoum F, Herskovitz M, Linder I, Ben Zeev B, Eyal S (2022) Using nirmatrelvir/ritonavir in patients with epilepsy: an update from the Israeli chapter of the International League Against Epilepsy. Epilepsia. https://doi.org/10.1111/epi.17212
3. US Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization for Paxlovid (nirmatrelvir and ritonavir). https://www.fda.gov/media/155050/download. Published December 22, 2021. Accessed 12 Mar 2022
4. Wang Z, Yang L (2022) In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery. J Med Virol 94(5):1766–1767. https://doi.org/10.1002/jmv.27540
5. Birbeck GL, French JA, Perucca E, Simpson DM, Fraimow H, George JM, Okulicz JF, Clifford DB, Hachad H, Levy RH, Quality Standards Subcommittee of the American Academy Of N, Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against E (2012) Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia 53(1):207–214. https://doi.org/10.1111/j.1528-1167.2011.03335.x
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献